Jubilant Ingrevia’s Board of Directors has approved the unaudited financial results for Q2 FY26, ended September 30, 2025. Key highlights include revenue from operations at ₹2027.26 crore and a profit before tax of ₹138.88 crore. The results reflect the company’s performance across its Speciality Chemicals, Nutrition & Health Solutions, and Chemical Intermediates segments. Earnings per share stood at ₹6.47.
Financial Performance
Jubilant Ingrevia Limited announced its unaudited standalone financial results for the quarter and half-year ended September 30, 2025. The company’s revenue from operations reached ₹2027.26 crore for the half-year. Profit before tax for the same period was reported at ₹138.88 crore.
Segment Highlights
The company’s performance across its key segments is noteworthy:
Speciality Chemicals: Revenue reached ₹1037.48 crore.
Nutrition & Health Solutions: Revenue reached ₹329.26 crore.
Chemical Intermediates: Revenue reached ₹772.43 crore.
Earnings Per Share
The basic and diluted earnings per share (EPS) for the period stood at ₹6.47.
Assets and Liabilities
Total assets were reported at ₹4597.86 crore. The company’s net worth reached ₹2509.47 crore.
Cash Flow
Net cash generated from operating activities for the half-year totaled ₹108.69 crore.
Auditor Review
The results have been reviewed by Walker Chandiok & Co LLP, Chartered Accountants, ensuring compliance with regulatory standards.
Consolidated Results Overview
The consolidated unaudited financial results show a revenue from operations of ₹2158.68 crore and a profit before tax of ₹192.63 crore.
Source: BSE
